Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating, because that oh-so familiar routine of online meetings and deadlines has, of course, returned. You knew this would happen, though, yes? After all, the world is round and keeps spinning, notwithstanding conspiracy theories. So to cope, we are brewing a cup or three of stimulation. Our choice today is the delicious cinnamon mocha. Please feel free to join us. Meanwhile, here are some tidbits. Hope your day goes well, and do stay in touch. …
AstraZeneca (AZN) chief executive officer Pascal Soriot is at the center of an extraordinary row among investors over his multi-million-dollar bonus, This is Money reports. Major shareholders are locked in heated talks after the drug maker proposed boosting his bonus and performance-related share award by $3.25 million to $17 million. The plan could take his overall pay above the $21.8 million he received last year. Two top shareholders, Aviva Investors and Standard Life Aberdeen, already voted to block the proposal ahead of the annual meeting on Tuesday.
About the Author Reprints
